Journal article
TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
Journal of clinical oncology, Vol.40(28), pp.3289-3300
06/03/2022
DOI: 10.1200/JCO.21.02506
PMCID: PMC9553389
PMID: 35658479
Abstract
The status of p53 in a tumor can be inferred by next-generation sequencing (NGS) or by immunohistochemistry (IHC). We examined the association between p53 IHC and sequence and whether p53 IHC alone, or integrated with
NGS, predicts the outcome.
From GOG-86P, a randomized phase II study of chemotherapy combined with either bevacizumab or temsirolimus in advanced endometrial cancer, 213 cases had p53 protein expression data measured by IHC and
NGS data. An analysis was designed to integrate p53 expression by IHC with the presence or absence of a
mutation. These variables were further correlated with progression-free survival (PFS) and overall survival (OS) in the chemotherapy plus bevacizumab arms versus the chemotherapy plus temsirolimus arm.
In the analysis of p53 IHC, the most striking treatment effect favoring bevacizumab was in cases where p53 was overexpressed (PFS hazard ratio [HR]: 0.46, 95% CI, 0.26 to 0.88; OS HR: 0.31, 95% CI, 0.16 to 0.62). On integrated analysis, patients with
missense mutations and p53 protein overexpression had a similar treatment effect on PFS (HR: 0.41, 95% CI, 0.22 to 0.83) and OS (HR: 0.28, 95% CI, 0.14 to 0.59) favoring bevacizumab plus chemotherapy relative to temsirolimus plus chemotherapy. Concordance between
NGS and p53 IHC was 88%. Concordance was 92% when cases with
mutations and
mutations or mismatch repair deficiency were removed.
IHC for p53 alone or when integrated with sequencing for
identifies a specific, high-risk tumor genotype/phenotype for which bevacizumab is particularly beneficial in improving outcomes when combined with chemotherapy.
Details
- Title: Subtitle
- TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
- Creators
- Kristina W Thiel - University of IowaEric J Devor - Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IAVirginia L Filiaci - NRG OncologyDavid Mutch - Washington University School of Medicine, Siteman Cancer Center, St Louis, MOKatherine Moxley - University of Oklahoma Health Sciences CenterAngeles Alvarez Secord - Duke University Health SystemKrishnansu S Tewari - University of California, Irvine Medical CenterMegan E McDonald - University of IowaCara Mathews - Brown UniversityCasey Cosgrove - The Ohio State University Wexner Medical CenterSummer Dewdney - Rush University Medical CenterCarol Aghajanian - Memorial Sloan Kettering Cancer and Weill Cornell Medical Center, New York, NYMegan I Samuelson - Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IAHeather A Lankes - Nationwide Children's HospitalRobert A Soslow - The University of New Mexico Health Sciences Center, Albuquerque, NMKimberly K Leslie - The University of New Mexico Health Sciences Center, Albuquerque, NM
- Resource Type
- Journal article
- Publication Details
- Journal of clinical oncology, Vol.40(28), pp.3289-3300
- DOI
- 10.1200/JCO.21.02506
- PMID
- 35658479
- PMCID
- PMC9553389
- NLM abbreviation
- J Clin Oncol
- eISSN
- 1527-7755
- Language
- English
- Date published
- 06/03/2022
- Academic Unit
- Pathology; Obstetrics and Gynecology
- Record Identifier
- 9984267241502771
Metrics
55 Record Views